Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2009

View Archived Issues

Phase I results position cancer vaccines MKC-1106 PP and MKC-1106 MT for phase II

Carboplatin-docetaxel combination beneficial in hormone-refractory prostate cancer

Novel compounds with preclinical antinociceptive activity disclosed by Abbott

Hematide is safe and increases Hb levels in CKD patients on hemodialysis

PBI-1402 shows renoprotective effects in mouse model of acute nephrotoxicity

Rosuvastatin reduces cardiac events in diabetic patients with ESRD

Preclinical data show potential of ALN-TTR for the treatment of ATTR / News in Context

Ironwood and Astellas sign licensing agreement for linaclotide in Japan and other territories

Cytokinetics presents update on phase I trials of CK-2017357

Evidence of genetic impact on response to LY-2140023 found

Sanofi-aventis and Regeneron expand collaboration for monoclonal antibodies

Phase IIa trial of Novavax's seasonal influenza vaccine in older adults under way

GSK begins largest malaria vaccine phase III trial in 7 African countries

GSK and Pfizer launch specialist HIV company ViiV Healthcare

Cytos Biotechnology updates the development of its hypertension vaccine

Cytopia and YM BioSciences amend terms of merger agreement

Novel antineoplastic agents claimed by Gilead

Urotensin II receptor antagonists in early development at sanofi-aventis

Concert Pharmaceuticals claims novel NDRIs for the treatment of depression

AMT reports results from preclinical study of gene therapy for DMD

Aastrom to initiate U.S. phase II clinical trial of catheter delivery of CRCs for DCM

New safety data supports continuation of Affymax's phase III program for Hematide

TapImmune and Crucell sign license agreement for PER.C6 cells in vaccine development

FDA approves CSL Biotherapies' application for accelerated approval of Afluria in children

TGA requests additional data from Acrux prior to marketing approval of Ellavie

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...